S S Raab1. 1. Department of Pathology and Laboratory Medicine, Medical College of Pennsylvania and Hahnemann University School of Medicine, Allegheny General Hospital, Pittsburgh, PA 15212-4772, USA. sraab@aherf.edu
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of immunohistochemistry. DESIGN: Using a theoretical decision analytic model, the cost-effectiveness of immunohistochemistry was evaluated in different scenarios depicting the beneficial use of immunohistochemistry. Data regarding the effectiveness of immunohistochemistry were obtained from the medical literature and costs were obtained from Allegheny General Hospital. SETTINGS: The scenarios depicted both private practice and university patients from which anatomic pathology specimens were obtained. Immunohistochemistry was subsequently performed on these specimens. MAIN OUTCOME MEASURES: Cost, life expectancy, diagnostic certainty, ability to predict prognosis, and cost-effectiveness were evaluated. RESULTS: In all scenarios, immunohistochemistry was cost-effective at very low efficacies. Assuming a per-antibody cost of $50 and use of a 5-antibody panel, immunohistochemistry was cost-effective if it resulted in a 1-year gain of population life expectancy in 1 or more of every 200 cases in which it was applied. Alternatively, if the gain in diagnostic certainty by using immunohistochemistry was 10% and the value placed on a percentage gain in diagnostic certainty was $1000, immunohistochemistry was cost-effective if it produced this increase in certainty in 1 of every 40 tests. If a life-year was valued at $50 000, immunohistochemistry was cost-effective if it resulted in a change in patient prognosis of 0.5 years in 1 of every 100 tests. CONCLUSIONS: Using theoretical modeling, immunohistochemistry is extremely cost-effective. These data have implications in an era of managed care when providers attempt to trim laboratory services. Additional studies are needed to evaluate the actual practice efficacy of immunohistochemistry.
OBJECTIVE: To evaluate the cost-effectiveness of immunohistochemistry. DESIGN: Using a theoretical decision analytic model, the cost-effectiveness of immunohistochemistry was evaluated in different scenarios depicting the beneficial use of immunohistochemistry. Data regarding the effectiveness of immunohistochemistry were obtained from the medical literature and costs were obtained from Allegheny General Hospital. SETTINGS: The scenarios depicted both private practice and university patients from which anatomic pathology specimens were obtained. Immunohistochemistry was subsequently performed on these specimens. MAIN OUTCOME MEASURES: Cost, life expectancy, diagnostic certainty, ability to predict prognosis, and cost-effectiveness were evaluated. RESULTS: In all scenarios, immunohistochemistry was cost-effective at very low efficacies. Assuming a per-antibody cost of $50 and use of a 5-antibody panel, immunohistochemistry was cost-effective if it resulted in a 1-year gain of population life expectancy in 1 or more of every 200 cases in which it was applied. Alternatively, if the gain in diagnostic certainty by using immunohistochemistry was 10% and the value placed on a percentage gain in diagnostic certainty was $1000, immunohistochemistry was cost-effective if it produced this increase in certainty in 1 of every 40 tests. If a life-year was valued at $50 000, immunohistochemistry was cost-effective if it resulted in a change in patient prognosis of 0.5 years in 1 of every 100 tests. CONCLUSIONS: Using theoretical modeling, immunohistochemistry is extremely cost-effective. These data have implications in an era of managed care when providers attempt to trim laboratory services. Additional studies are needed to evaluate the actual practice efficacy of immunohistochemistry.
Authors: Matthew G Hanna; Victor E Reuter; Jennifer Samboy; Christine England; Lorraine Corsale; Samson W Fine; Narasimhan P Agaram; Evangelos Stamelos; Yukako Yagi; Meera Hameed; David S Klimstra; S Joseph Sirintrapun Journal: Arch Pathol Lab Med Date: 2019-06-11 Impact factor: 5.534
Authors: Amanda Khoo; Lydia Y Liu; Julius O Nyalwidhe; O John Semmes; Danny Vesprini; Michelle R Downes; Paul C Boutros; Stanley K Liu; Thomas Kislinger Journal: Nat Rev Urol Date: 2021-08-27 Impact factor: 14.432
Authors: Lik Hang Lee; Lindy Davis; Lourdes Ylagan; Angela R Omilian; Kristopher Attwood; Canan Firat; Jinru Shia; Philip B Paty; William G Cance Journal: J Natl Cancer Inst Date: 2022-05-09 Impact factor: 11.816
Authors: Leandro Luongo de Matos; Damila Cristina Trufelli; Maria Graciela Luongo de Matos; Maria Aparecida da Silva Pinhal Journal: Biomark Insights Date: 2010-02-09
Authors: Caitlin J May; Michael W Piepkorn; Stevan R Knezevich; David E Elder; Raymond L Barnhill; Annie C Lee; Martiniano J Flores; Kathleen F Kerr; Lisa M Reisch; Joann G Elmore Journal: J Cutan Pathol Date: 2020-07-17 Impact factor: 1.587